- Associated Press - Thursday, April 27, 2017

LONDON (AP) - Anglo-Swedish drugmaker AstraZeneca says first-quarter revenue fell amid declining sales of cholesterol treatment Crestor, which lost patent protection last year.

Total revenue declined 12 percent to $5.4 billion as Crestor sales dropped 45 percent. Net income fell to $537 million, from $646 million.

CEO Pascal Soriot said Thursday that the impact of recent patent expirations should ease this year as he highlighted optimism about new cancer treatments in “what we expect to be a pivotal year for AstraZeneca.”

Sales of cancer drugs rose 20 percent to $885 million, driven by the introduction of the lung cancer treatment Tagrisso. Sales of Tagrisso were $171 million. Soriot also highlighted “positive data” for Lynparza, a treatment for ovarian and breast cancer that is now available in 31 countries.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide